Compare Nuvalent Inc (NUVL) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Wendys Co — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Wendys Co trades at $7.61 (market cap $1.50B). The key difference: Nuvalent Inc is far larger — about 6.5× Wendys Co's market cap, and Wendys Co pays a 7.13% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | WEN | |
|---|---|---|
Market Cap | $9.81B | $1.50B |
Sector | Technology | Consumer Cyclical |
52-Week High | $123.96 | $11.33 |
52-Week Low | $72.16 | $6.17 |
Enterprise Value | $8.52B | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Wendy's (WEN) trades at $7.63, down 1.68% on the day, with a bullish technical signal from moving averages and recent meme stock momentum. The company shows consistent earnings beats but faces margin pressure, with net income declining from $204M in 2023 to $165M in 2025. Valuation metrics appear attractive with a P/E of 10.2 and P/S of 0.69, while analyst consensus is mixed with a $7.96 price target.
The stock presents a value opportunity with solid dividends and low valuation, but investors face risks from declining profitability, high debt levels, and competitive pressures. Near-term catalysts include Q2 2026 earnings on August 7 and ongoing Project Fresh initiatives, though weak traffic and cost inflation remain headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
